EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adaptive Biotechnologies's Enterprise Value is €2,861.3 Mil.
Adaptive Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-25.5 Mil. Therefore, Adaptive Biotechnologies's EV-to-FCF for today is -112.24.
The historical rank and industry rank for Adaptive Biotechnologies's EV-to-FCF or its related term are showing as below:
HAM:1HM'
s EV-to-FCF Range Over the Past 10 Years
Min: -110.27 Med: -6.54 Max: 22.27
Current: -110.27
During the past 9 years, the highest EV-to-FCF of Adaptive Biotechnologies was 22.27. The lowest was -110.27. And the median was -6.54.
HAM:1HM's EV-to-FCF is ranked worse than 100% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.975
vs HAM:1HM: -110.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adaptive Biotechnologies's PE Ratio (TTM) for today is calculated as:
Adaptive Biotechnologies's share price for today is €18.54.
Adaptive Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.285.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adaptive Biotechnologies EV-to-FCF Related Terms
Adaptive Biotechnologies EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's EV-to-FCF falls into.
Adaptive Biotechnologies's current Enterprise Value is €2,861.3 Mil.
Adaptive Biotechnologies's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-25.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (HAM:1HM) has a EV-to-FCF of -112.24 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry.
Is Adaptive Biotechnologies' EV-to-FCF too high?
Adaptive Biotechnologies' current EV-to-FCF is -112.24. Based on the distribution chart, Adaptive Biotechnologies ranks #999999 out of 98 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Adaptive Biotechnologies has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' EV-to-FCF compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #999999 out of 98 companies for EV-to-FCF. This places Adaptive Biotechnologies in the lower half of its industry. The industry median EV-to-FCF is 22.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.98, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adaptive Biotechnologies and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adaptive Biotechnologies's current EV-to-FCF is -112.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (HAM:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.80, compared to a current price of €18.54 — trading 110.7% above its estimated fair value. The current EV-to-FCF is -112.24. Adaptive Biotechnologies' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Adaptive Biotechnologies (HAM:1HM), the current EV-to-FCF is -112.24 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (HAM:1HM) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of €18.54 is trading 110.7% above its estimated GF Value™ of €8.80.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for HAM:1HM:
EV-to-FCF: -112.24
GF Value™: €8.80 vs. price of €18.54 (110.7% above fair value)
No single metric tells the full story. See the HAM:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
47GF Score
Get the complete analysis for HAM:1HM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:1HM has been successfully added to your 
